Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

AVNR

551 Posts
Pagina: «« 1 2 3 4 5 6 ... 28 »» | Laatste | Omlaag ↓
  7. [verwijderd] 23 april 2007 14:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    AVANIR Pharmaceuticals Invites Investors to Second Quarter Conference Call and Provides Preliminary Results for Second Quarter and Business Highlights
    Monday April 23, 8:30 am ET

    ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR - News) today provided preliminary results and a business update for the second quarter and announced that it will release complete financial results for the three and six months ended March 31, 2007 before market open on Wednesday, May 9, 2007. Keith Katkin, President and Chief Executive Officer, Michael Puntoriero, Senior Vice President and Chief Financial Officer, and Randall Kaye, M.D., Senior Vice President and Chief Medical Officer, will host an investment community conference call that same day at 8:00 a.m. Pacific time / 11:00 a.m. Eastern time to discuss those results and answer questions.
    Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com. To listen to the live call, please go to AVANIR's website prior to the start of the call to register, download and install the necessary audio software.

    A webcast replay will be available on AVANIR's website for 30 days, and a telephone replay will be available through May 14, 2007, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 5305269.

    Preliminary Results

    Preliminary results for the quarter ended March 31, 2007 are provided below, along with a summary of certain business highlights for the quarter:

    Total net revenues for the quarter are expected to be $6.1 million, including FazaClo® net revenues of approximately $4.1 million. FazaClo net wholesaler shipments for the quarter ended March 31, 2007 were approximately $4.2 million.
    Estimated operating loss for the quarter is expected to be in the range of between $11.0 million and $12.5 million, excluding the impact, if any this quarter, from the downsizing of the San Diego research facilities.
    Raised net proceeds of approximately $6.9 million from the sale of 3.2 million shares of common stock into the open market under the offering prospectus on file with the SEC.
    Total outstanding notes under the Alamo Pharmaceuticals purchase agreement at March 31, 2007 was $22.3 million. This amount increased over the prior quarter by a net amount of $600,000 due to the issuance of an additional $2 million note following the achievement of a revenue-related earn out milestone. This increase was partially offset with the payment to the note holder of $1.4 million, generated from equity offering proceeds.
    Completed the quarter with cash, cash equivalents, investments in securities and restricted cash of $8.7 million.
    Other Business Highlights

    Announced that after a meeting with officials of the U.S. Food and Drug Administration (FDA) in late February 2007, that AVANIR will conduct an additional trial in patients with IEED to confirm that a proposed lower does is safe and effective. Also announced that the Company has agreed to initiate certain preclinical and clinical pharmacology studies involving Zenvia(TM). The Company is currently working with the FDA on clinical trial design.
    Announced that Keith Katkin, formerly Sr. VP of Sales and Marketing, was elected President and CEO and appointed to the Board of Directors following the departure of Eric Brandt. The Company also announced that Randall Kaye, M.D., formerly Vice President, Clinical and Medical Affairs, was elected Senior Vice President and Chief Medical Officer.
    Announced that the Company is in discussions with several parties that have expressed interest in potentially acquiring certain Company assets, including FazaClo and several investigational compounds. These discussions remain ongoing, although no definitive terms have been reached for any transaction.
    Announced that Novartis plans to advance the lead candidate for the Macrophage Migration Inhibitor Factor (MIF) program, AVP-28225, towards clinical development. Also, that AVANIR's research collaboration agreements with AstraZeneca and Novartis will end in the third fiscal quarter and that the Company will receive no additional revenues from these collaborations once they terminate.
    Further, the Company announced that it has initiated planning to reduce ongoing operational costs associated with the loss of revenues from the collaboration arrangements and that the Company expects to reduce headcount in San Diego and seek to sublease a substantial portion of its remaining space in San Diego. The Company expects to terminate approximately 20 employees in San Diego during the current quarter and is in discussions regarding the proposed sublease of its San Diego lab facilities.
    Reported that the audit committee of the Board of directors dismissed Deloitte & Touche LLP as the Company's independent auditors and has engaged KMJ Corbin & Company to serve in that capacity.
    Following the end of the quarter, AVANIR announced positive results of the Phase III study for Zenvia in diabetic neuropathic pain.

    biz.yahoo.com/bw/070423/2007042300549...
  9. [verwijderd] 23 april 2007 15:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    April 23 (Reuters) - Avanir Pharmaceuticals (AVNR.O: Quote, Profile , Research) said it expects to post second-quarter operating loss of $11.0 million to $12.5 million, excluding the impact from downsizing research facilities in San Diego.

    The pharmaceutical company expects to post second-quarter net revenues of $6.1 million. (Reporting by Shivani Singh in Bangalore)

  14. [verwijderd] 26 april 2007 14:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Extended Trading

    FlashQuotes InfoQuotes Summary Quote Charts Revenue / EPS Summary Company Financials - View Competitors - Short Interest Company News Analyst Info Stock Report Real-Time SEC Filings - Holdings/Insider Summary - Institutional Holdings - Insider Form 4 Equity Options Extended Trading Company Research - StockConsultant - Guru Analysis Annual Report AVNR







    AVANIR Pharmaceuticals

    Pre-Market | After Hours Market Apr. 25, 2007 Market Close: $ 3.40




    Pre-Market Trade Reporting Thursday April 26


    Pre-Market
    Last: $ 3.56 Pre-Market
    High: $ 3.57
    Pre-Market
    Volume: 14,401 Pre-Market
    Low: $ 3.45

    Pre-Market
    Time (ET) Pre-Market
    Price Pre-Market
    Share Volume
    08:14 $ 3.56 500
    08:13 $ 3.54 1,000
    08:13 $ 3.54 1,000
    08:13 $ 3.57 881
    08:13 $ 3.57 119
    08:13 $ 3.54 1,500
    08:12 $ 3.54 351
    08:12 $ 3.54 500
    08:11 $ 3.55 200
    08:10 $ 3.55 1,000
    08:09 $ 3.54 1,080
    08:07 $ 3.54 200
    08:07 $ 3.54 220
    08:06 $ 3.54 1,000
    08:05 $ 3.50 551
    08:05 $ 3.50 200
    08:03 $ 3.49 1,500
    08:03 $ 3.50 949
    08:03 $ 3.50 500
    08:01 $ 3.47 810
    08:00 $ 3.45 150
    08:00 $ 3.47 190







    Nu springt iedereen er weer bestens in hoor,let maar op,ze gaan hem weer een stuk hoger zetten na de enorme daling vanaf 6,70 vorige week.
  17. [verwijderd] 2 mei 2007 16:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
    Tuesday May 1, 2:14 pm ET
    *Study Reveals More Than 1.8 Million US Patients Afflicted with IEED*
    *Data Indicates Zenvia Treatment Appears Safe and Well Tolerated in Patients Treated for More Than One Year*

    ALISO VIEJO, Calif.--(BUSINESS WIRE)--Avanir Pharmaceuticals (NASDAQ:AVNR - News) today announced that data on the long-term safety of the investigational drug Zenvia(TM) (dextromethorphan / quinidine) and the prevalence of Involuntary Emotional Expression Disorder (IEED) were presented today during a poster session at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. The information was presented in the following posters:
    1. Poster P01.090: Involuntary Emotional Expression Disorder
    (IEED) Prevalence and Treatment

    2. Poster P01.015: Long-Term Safety of AVP-923
    (Dextromethorphan/Quinidine) in the Treatment of Involuntary
    Emotional Expression Disorder (IEED)

    3. Poster P01.016: Competitive Binding of Dextromethorphan to
    Selective Brain Receptor Sites

  18. [verwijderd] 12 mei 2007 20:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    In de gaten houden deze!is langzaam terug gezakt de laatste tijd naar 2,65 nu.Heeft groot potencieel en bij goedkeuring weer een paar keer over de kop denk ik.
  19. [verwijderd] 14 mei 2007 12:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    As of March 31, 2007, we had cash and investments in securities totaling $8.7 million, including cash and cash equivalents of $5.3 million, short and long-term investments in securities of $2.2 million and restricted investments in securities of $1.2 million. After the end of the quarter, the Company reported raising additional net proceeds of approximately $7.2 million from the sale of 2.2 million shares of common stock into the open market under the offering prospectus filed with the Securities and Exchange Commission (SEC).

    Zeer gevaarlijk, het bedrijf heeft een chronisch tekort aan cash.
  20. [verwijderd] 14 mei 2007 22:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zeer gevaarlijk,dat is zeker waar.Maar ik heb er net voor sluiten toch maar even flink wat ingeslagen op 2,41!ik verwacht hem deze week nog weer boven de 3!
551 Posts
Pagina: «« 1 2 3 4 5 6 ... 28 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.854
AB InBev 2 5.311
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.290
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 9.055
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 167
ADMA Biologics 1 32
Adomos 1 126
AdUX 2 457
Adyen 13 16.733
Aedifica 2 844
Aegon 3.257 320.420
AFC Ajax 537 7.029
Affimed NV 2 5.806
ageas 5.843 109.790
Agfa-Gevaert 13 1.901
Ahold 3.536 74.034
Air France - KLM 1.024 34.397
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.779
Alfen 13 17.529
Allfunds Group 3 1.240
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 342
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.779
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.567
AMG 965 126.759
AMS 3 73
Amsterdam Commodities 303 6.527
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.211
Apollo Alternative Assets 1 17
Apple 5 322
Arcadis 251 8.630
Arcelor Mittal 2.024 318.793
Archos 1 1
Arcona Property Fund 1 272
arGEN-X 15 9.196
Aroundtown SA 1 190
Arrowhead Research 5 9.317
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.789
ASML 1.762 77.899
ASR Nederland 18 4.166
ATAI Life Sciences 1 7
Atenor Group 1 347
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.820
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.686

Macro & Bedrijfsagenda

  1. 29 mei

    1. Consumentenvertrouwen juni (Dld)
    2. Consumentenvertrouwen mei (Fra)
    3. ASR jaarvergadering
    4. Hypotheekaanvragen - wekelijks (VS)
    5. Inflatie mei, vlpg (Dld)
    6. OCI jaarvergadering
    7. Federal Reserve - Beige Book (VS)
    8. HP Q2-cijfers (VS)
    9. Salesforce Q1-cijfers (VS)

  2. 30 mei

    1. Azerion Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda